Institute of Biomedical Research Corp. (MRES)
USD 0.01
(5.38%)
USD 0.01
(5.38%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2010 | 76.35 Thousand USD | -1.62% |
| 2009 | 77.61 Thousand USD | -25.36% |
| 2008 | 103.97 Thousand USD | 0.0% |
| 2007 | - USD | -100.0% |
| 2006 | 111.18 Thousand USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2010 Q2 | 680.47 Thousand USD | 791.2% |
| 2010 FY | 76.35 Thousand USD | -1.62% |
| 2010 Q3 | 667.53 Thousand USD | -1.9% |
| 2010 Q4 | 654.6 Thousand USD | -1.94% |
| 2010 Q1 | 76.35 Thousand USD | 2.28% |
| 2009 Q4 | 74.64 Thousand USD | 14.58% |
| 2009 Q3 | 65.14 Thousand USD | -8.41% |
| 2009 FY | 77.61 Thousand USD | -25.36% |
| 2009 Q1 | 77.61 Thousand USD | -7.72% |
| 2009 Q2 | 71.13 Thousand USD | -8.35% |
| 2008 FY | 103.97 Thousand USD | 0.0% |
| 2008 Q4 | 84.09 Thousand USD | -9.8% |
| 2008 Q2 | 103.79 Thousand USD | -0.18% |
| 2008 Q1 | 103.97 Thousand USD | 22.6% |
| 2008 Q3 | 93.24 Thousand USD | -10.17% |
| 2007 FY | - USD | -100.0% |
| 2007 Q1 | - USD | -100.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q4 | 84.81 Thousand USD | 0.0% |
| 2006 Q3 | 116.29 Thousand USD | -0.1% |
| 2006 Q4 | 111.78 Thousand USD | -3.88% |
| 2006 Q2 | 116.41 Thousand USD | 4.7% |
| 2006 Q1 | 111.18 Thousand USD | -32.29% |
| 2006 FY | 111.18 Thousand USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q3 | 202.2 Thousand USD | 0.0% |
| 2005 Q4 | 164.21 Thousand USD | -18.79% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -3205.368% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 96.101% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 99.277% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 86.171% |
| Rebus Holdings, Inc. | 5000.00 USD | -1427.08% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.941% |
| Qrons Inc. | 420.00 USD | -18079.524% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 90.092% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 99.727% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | 84.111% |
| Skye Bioscience, Inc. | 11.94 Million USD | 99.361% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 99.803% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 98.942% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.929% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 94.668% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -5.512% |
| Mesoblast Limited | 667.9 Million USD | 99.989% |
| Marizyme, Inc. | 22.01 Million USD | 99.653% |
| Genus plc | 1.02 Billion USD | 99.993% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 94.379% |
| Pharming Group N.V. | 462.85 Million USD | 99.984% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 97.695% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | 84.7% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 87.822% |
| ContraFect Corporation | 20.67 Million USD | 99.631% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | 80.44% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | 80.021% |
| IMV Inc. | 31.33 Million USD | 99.756% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 98.158% |
| MultiCell Technologies, Inc. | 126.22 USD | -60392.79% |
| ONE Bio Corp. | 70.08 Million USD | 99.891% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 91.875% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.941% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | 82.314% |
| Q BioMed Inc. | 3.51 Million USD | 97.828% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 99.783% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | 70.777% |
| Biomind Labs Inc. | 73.81 Thousand USD | -3.434% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.983% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 94.73% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 99.746% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 97.22% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 88.894% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 97.067% |
| GB Sciences, Inc. | 103.44 Thousand USD | 26.187% |
| Alpha Cognition Inc. | 2.45 Million USD | 96.886% |
| HST Global, Inc. | 1526.00 USD | -4903.539% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 92.272% |
| Halberd Corporation | 10.13 Thousand USD | -653.667% |
| Enzolytics Inc. | 361.7 Million USD | 99.979% |
| Agentix Corp. | 261.39 Thousand USD | 70.789% |
| Resverlogix Corp. | 8.11 Million USD | 99.059% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 95.934% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.998% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 99.84% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 88.063% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -235.165% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 99.147% |
| AVAX Technologies, Inc. | 7.37 Million USD | 98.965% |
| Zenith Capital Corp. | 7410.00 USD | -930.418% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.998% |
| Ember Therapeutics, Inc. | 184.00 USD | -41396.739% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | 76.273% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | 70.786% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 91.772% |
| Kadimastem Ltd | 2.3 Million USD | 96.686% |
| Helix BioMedix, Inc. | 3.02 Million USD | 97.476% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 99.855% |
| BioStem Technologies, Inc. | 14.56 Million USD | 99.476% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -33.734% |
| LadRx Corporation | 2.3 Million USD | 96.692% |
| Cell Source, Inc. | 195.17 Thousand USD | 60.878% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 78.408% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 78.408% |
| NovAccess Global Inc. | 62.24 Thousand USD | -22.661% |
| Affymax, Inc. | 7.44 Million USD | 98.974% |
| Itoco Inc. | 1.4 Million USD | 94.546% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | 20.179% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | 27.968% |
| Mobile Lads Corp. | 52.00 USD | -146734.615% |
| CytoDyn Inc. | 11.13 Million USD | 99.314% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | 46.595% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -327.036% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | 80.192% |
| SYBLEU INC | 330.46 Thousand USD | 76.895% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | 81.351% |
| International Stem Cell Corporation | 5.39 Million USD | 98.583% |
| Bioxytran, Inc. | 137.63 Thousand USD | 44.525% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 99.491% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 99.539% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | 3.349% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 91.17% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 98.984% |
| Neutra Corp. | 2851.00 USD | -2578.148% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 99.764% |
| PureTech Health plc | 693.97 Million USD | 99.989% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 99.054% |
| IXICO plc | 15.84 Million USD | 99.518% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 99.078% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.926% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Cellectis S.A. | 333.99 Million USD | 99.977% |